{"id":{"repo_id":"vt","oai_identifier":"oai:vtechworks.lib.vt.edu:10919/30940"},"canonical_url":"https://search.dev.ndltd.org/etd/vt/oai:vtechworks.lib.vt.edu:10919/30940","repository":{"repo_id":"vt","name":"Virginia Tech","base_url":"https://vtechworks.lib.vt.edu/oai/request"},"display":{"title":"Synthesis and Antiproliferative Activity of C3' and B-ring Modified Paclitaxel Analogs","abstract":"The natural product, paclitaxel, has made tremendous contributions in supplying the arsenal of anticancer therapeutics, and was FDA approved for clinical use in 1992. In order to design simplified analogs, the conformation that paclitaxel adopts when binding to tubulin has been the subject of ongoing studies. Much evidence has led to a T-taxol proposal and a C3' constrained analog has been designed and synthesized as a test of this conformation. In the search for more active analogs, a number of modifications have been made to paclitaxel by other researchers. However, the nature of the alterations, and combinations thereof, have not been exhausted. To this end, synthesis of northern hemisphere B-ring analogs is underway.","abstract_html":"The natural product, paclitaxel, has made tremendous contributions in supplying the arsenal of anticancer therapeutics, and was FDA approved for clinical use in 1992. In order to design simplified analogs, the conformation that paclitaxel adopts when binding to tubulin has been the subject of ongoing studies. Much evidence has led to a T-taxol proposal and a C3' constrained analog has been designed and synthesized as a test of this conformation. In the search for more active analogs, a number of modifications have been made to paclitaxel by other researchers. However, the nature of the alterations, and combinations thereof, have not been exhausted. To this end, synthesis of northern hemisphere B-ring analogs is underway.","abstract_has_math":false,"creators":["Hodge, Mathis"],"institution":"Virginia Tech","degree_name":"Master of Science","degree_level":"masters","degree_discipline":"Chemistry","degree_department":"Chemistry","school":null,"contributors":[],"advisors":[],"committee_chairs":["Kingston, David G. I."],"committee_members":["Deck, Paul A.","Carlier, Paul R."],"year":2007,"date_issued":"2007-11-02","date_published":"2007-11-02","updated_at":"2026-07-22T22:20:05Z","subjects":["Microtubules","Chemotherapy","Antiproliferative","Cancer","Taxol","Paclitaxel"],"languages":[],"rights":["In Copyright"],"rights_urls":["http://rightsstatements.org/vocab/InC/1.0/"],"identifier_entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["etd-01142008-104557"],"render_values":[{"text":"etd-01142008-104557","href":null,"code":true}]}]},"links":{"outbound_url":"http://hdl.handle.net/10919/30940","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.committeechair","label":"Committee Chair","values":["Kingston, David G. I."]},{"key":"dc:contributor.committeemember","label":"Committee Member","values":["Deck, Paul A.","Carlier, Paul R."]},{"key":"dc:contributor.department","label":"Department","values":["Chemistry"]},{"key":"dc:creator","label":"Author","values":["Hodge, Mathis"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2014-03-14T20:30:38Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2014-03-14T20:30:38Z","2008-02-16"]},{"key":"dc:date.issued","label":"Date","values":["2007-11-02"]},{"key":"dc:publisher","label":"Institution","values":["Virginia Tech"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["masters"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Master of Science"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Virginia Polytechnic Institute and State University"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Microtubules","Chemotherapy","Antiproliferative","Cancer","Taxol","Paclitaxel"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:rights","label":"Dc Rights","values":["In Copyright"]},{"key":"dc:rights.uri","label":"Rights URI","values":["http://rightsstatements.org/vocab/InC/1.0/"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.other","label":"Dc Identifier Other","values":["etd-01142008-104557"]},{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10919/30940"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["The natural product, paclitaxel, has made tremendous contributions in supplying the arsenal of anticancer therapeutics, and was FDA approved for clinical use in 1992. In order to design simplified analogs, the conformation that paclitaxel adopts when binding to tubulin has been the subject of ongoing studies. Much evidence has led to a T-taxol proposal and a C3' constrained analog has been designed and synthesized as a test of this conformation. In the search for more active analogs, a number of modifications have been made to paclitaxel by other researchers. However, the nature of the alterations, and combinations thereof, have not been exhausted. To this end, synthesis of northern hemisphere B-ring analogs is underway."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Master of Science"]},{"key":"dc:title","label":"Title","values":["Synthesis and Antiproliferative Activity of C3' and B-ring Modified Paclitaxel Analogs"]}]}],"canonical_facts":{"dc:contributor.committeechair":["Kingston, David G. I."],"dc:contributor.committeemember":["Deck, Paul A.","Carlier, Paul R."],"dc:contributor.department":["Chemistry"],"dc:creator":["Hodge, Mathis"],"dc:date.accessioned":["2014-03-14T20:30:38Z"],"dc:date.available":["2014-03-14T20:30:38Z","2008-02-16"],"dc:date.issued":["2007-11-02"],"dc:description.abstract":["The natural product, paclitaxel, has made tremendous contributions in supplying the arsenal of anticancer therapeutics, and was FDA approved for clinical use in 1992. In order to design simplified analogs, the conformation that paclitaxel adopts when binding to tubulin has been the subject of ongoing studies. Much evidence has led to a T-taxol proposal and a C3' constrained analog has been designed and synthesized as a test of this conformation. In the search for more active analogs, a number of modifications have been made to paclitaxel by other researchers. However, the nature of the alterations, and combinations thereof, have not been exhausted. To this end, synthesis of northern hemisphere B-ring analogs is underway."],"dc:description.degree":["Master of Science"],"dc:identifier.other":["etd-01142008-104557"],"dc:identifier.uri":["http://hdl.handle.net/10919/30940"],"dc:publisher":["Virginia Tech"],"dc:rights":["In Copyright"],"dc:rights.uri":["http://rightsstatements.org/vocab/InC/1.0/"],"dc:subject":["Microtubules","Chemotherapy","Antiproliferative","Cancer","Taxol","Paclitaxel"],"dc:title":["Synthesis and Antiproliferative Activity of C3' and B-ring Modified Paclitaxel Analogs"],"dc:type":["Thesis"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["masters"],"thesis:degree_name":["Master of Science"],"thesis:institution_name":["Virginia Polytechnic Institute and State University"]},"updated_at":"2026-07-22T22:20:05Z"}